What is Thymosin Alpha-1 (Tal) Injection ?
Thymosin Alpha-1 (Tal) is a synthetic 28-amino acid peptide originally isolated from the thymus gland. It is an immunomodulatory and immune-enhancing peptide that helps regulate and restore immune function.
It was first approved in several countries (e.g., under the brand Zadaxin®) for treatment of viral infections and as an immune adjuvant in cancer therapy.
Mechanism Of Action
Enhances T-cell differentiation and activity
Increases cytotoxic T-cell and natural killer (NK) cell function
Promotes cytokine regulation (e.g., IL-2, IFN-v)
Improves antigen presentation and immune surveillance
Approved / Recognized Uses
- Chronic Hepatitis B and Hepatitis C
- Immunodeficiency disorders
- Cancer adjuvant therapy (especially in combination with chemotherapy)
- Sepsis or post-surgical infections
Off Label Uses
- Autoimmune diseases (to modulate overactive immune response)
- Anti-aging / immune optimization
- Chronic fatigue or immune dysregulation syndromes
Dose & Administration
1.6 mg to 3.2 mg, twice per week, administered subcutaneously
2 to 6 months, depending on indication and clinical response
Common Cycles
- Injection Guidelines
- Typical Regimen
- Hepatitis B / C
- Immune modulation / wellness
- Cancer adjuvant
- COVID-19 / viral support
- 1.6 mg twice weekly
- 1.6 mg twice weekly
- 1.6–3.2 mg twice weekly
- 1.6 mg daily or twice weekly
- 6–12 months
- 4–8 weeks (repeated cycles possible)
- As per oncologic cycle
- 2–4 weeks (short course)
- Duration
Route: Subcutaneous (preferred)
Injection sites: Upper arm, thigh, or abdomen (rotate sites)